NMS 293
Alternative Names: NMS-03305293; NMS-293; NMS-P293Latest Information Update: 11 Jun 2025
At a glance
- Originator Nerviano Medical Sciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Astrocytoma; Glioblastoma
- Phase I Ovarian cancer; Small cell lung cancer; Solid tumours
- No development reported Breast cancer
Most Recent Events
- 28 Apr 2025 Phase-I clinical trials in Ovarian cancer (Second-line therapy or greater, Combination therapy) (PO) (NCT06930755)
- 28 Apr 2025 Phase-I clinical trials in Small cell lung cancer (Combination therapy, Second-line therapy or greater) (PO) (NCT06931626)
- 16 Apr 2025 Nerviano Medical Sciences plans a phase I trial for Ovarian Cancer (Combination therapy, Second-line therapy or greater, Recurrent) in unknown location (PO) (NCT06930755)